Psychosis in Parkinson’s disease (PD) is a fairly common and vexing problem. Although it can occur at any stage of the illness, it is a particularly important issue for patients who are in the later stages of PD and have been chronically treated with anti-PD medications. The exact pathophysiology of PD-related psychosis remains a mystery. Neurochemical imbalances, sleep disturbances, and visual processing abnormalities in PD have been implicated in its pathogenesis. Treatment of psychotic symptoms should occur only after potential medical and environmental causes of delirium have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient’s anti-PD medications to those that are necessary to preserve motor function. Should that fail, an atypical antipsychotic agent is presently the treatment of choice. An emerging treatment option is the use of acetylcholinesterase inhibitors. This article reviews what is known about the epidemiology, risk factors, pathophysiology, and treatment of PD-related psychosis. (J Geriatr Psychiatry Neurol 2004; 17:127-136)
3. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol1970; 23:193-200.
4.
4. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry2001; 70:727-733.
5.
5. Fénelon G, Mahieux F, Huon R, Ziegler M.Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain2000; 123:733-745.
7. Aarsland D, Larsen JP, Cummins JL. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol1999; 56:595-601.
8.
8. Sadock BJ, Sadock VA, eds. Kaplan and Sadock’s comprehensive textbook of psychiatry seventh edition on CD-ROM. Philadelphia: Lippincott Williams & Wilkins, 2000.
9.
9. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Mov Disord1998; 13:20-28.
10.
10. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology1993; 43:2227-2229.
11.
11. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology1995; 45(4):669-671.
12.
12. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology2001; 57:2078-2082.
13.
13. Melamed E.Neurobehavioral abnormalities in Parkinson’s disease. In:Watts RL, Koller WC, eds. Movement disorders. New York: McGraw Hill, 1996:257-262.
14.
14. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology1998; 51(3):811-814.
15.
15. Rinne UK. Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand1983; 95(suppl):107-111.
16.
16. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson’s disease: a populational study. Ann Neurol1983; 14:136-136.
17.
17. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189-198.
18.
18. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm2000; 107:59-71.
20. Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord1999; 14:117-121.
21.
21. Glenthøj BY, Hemmingsen R.Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry1997; 21:23-46.
22.
22. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry1973; 29:35-40.
23.
23. Sato M, Chen CC, Akiyama K, et al. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry1983; 18:429-440.
24.
24. Sato M, Numachi Y, Hamamura T.Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull1992; 18:115-122.
25.
25. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry2001; 70:734-738.
26.
26. Klein C, Kömpf D, Pulkowski U, et al. A study of visual hallucinations in patients with Parkinson’s disease. J Neurol1997; 244:371-377.
27.
27. Aghajanian G, Marek G.Serotonin and hallucinogens. Neuropsychopharmacology. 1999; 21(suppl 1):S16-S23.
28.
28. Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA (“ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology2000; 23:396-404.
29.
29. Richelson E.Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry1999; 60(suppl 10):5-14.
30.
30. Perry EK, Perry RH. Acetylcholine and hallucinations: diseaserelated compared to drug-induced alterations in human consciousness. Brain Cognit1995; 28:240-258.
31.
31. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol1986; 45:393-396.
32.
32. Nakano I, Hirano A.Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol1984; 15:415-418.
33.
33. Goetz CG, Tanner CM, Klawans MD. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry1982; 139(4):494-497.
34.
34. Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness?Trends Neurosci1999; 22:273-280.
35.
35. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry1978; 135:669-675.
36.
36. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson’s disease. Neurology2000; 55:281-288.
37.
37. Manni R, Pacchetti C, Terzaghi M, et al. Hallucinations and sleep-wake cycle in PD. Neurology2002; 59:1979-1981.
38.
38. Bodis-Wollner I.Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci1990; 13:296-302.
39.
39. Bodis-Wollner I.Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat Disord2003; 9:S83-S89.
40.
40. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol1998; 21:289-295.
41.
41. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol2002; 59:1249-1252.
42.
42. Barnes J, Boubert L, Harris J, et al. Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia2003; 41:565-574.
43.
43. Goetz, CG. Hallucinations and parkinsonism. Key note address. Presented at: Seventeenth Annual Symposia on Etiology Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. October 19, 2003; Parkinson Study Group Meeting.
44.
44. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson’s disease. Clin Neuropharmacol2000; 23(5):287-289.
45.
45. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord1997; 12:483-496
46.
46. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol1991; 14:283-295.
47.
47. Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs1999.
48.
48. Friedman JH, Fernandez HH. The non-motor problems of Parkinson’s disease. Neurology2000; 6:18-27.
49.
49. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson’s disease. Expert Opin Pharmacother2003; 4:1747-1761.
50.
50. Fernandez HH, Trieschmann ME, Friedman JH. The treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf2003; 26:643-659.
51.
51. Fernandez HH, Trieschmann ME, Okun MS. “Rebound psychosis”: effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord, in press.
52.
52. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2 and serotonin 2 pK values. J Pharmacol Exp Ther1989; 251:238-246.
53.
53. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord2000; 151:201-211.
54.
54. Pakkenberg H, Pakkenberg B.Clozapine in the treatment of tremor. Acta Neurol Scand1986; 73:295-297.
55.
55. Fischer P, Danielczyk W, Simanyi M, Streifler MB. Dopaminergic psychosis in advanced Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology, vol 53. Parkinson’s disease: anatomy, pathology and therapy. New York: Raven; 1990:391-397.
57. Friedman JH, Lannon MC. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology1997; 4:1077-1081.
58.
58. Bonnucelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson’s disease tremor: effects of acute and chronic administration. Neurology1997; 49:1587-1590.
59.
59. Jansen ENH. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand1994; 89:262-265.
60.
60. Wolters ECH, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology1990; 40:832-834.
61.
61. Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med1999; 340:757-763.
62.
62. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet1999; 353:2041-2042.
63.
63. Greene P, Cote L, Fahn S.Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. In: Narabayashi N, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, Parkinson’s disease: from basic research to treatment. New York: Raven, 1993:702-706.
64.
64. Rudolf J, Grond M, Neveling M, Heiss W.Clozapine-induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J Neural Transm1997; 104:1305-1311.
65.
65. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence based review. Mov Disord2002; 17:S120-S127.
66.
66. Fernandez HH, Donnelly EM, Friedman JH. Long-term out-come of clozapine use for psychosis among parkinsonian patients. Mov Disord, in press.
67.
67. Arnt J, Skarsfeld T.Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology1998; 18:63-101.
68.
68. Grant S, Fiton A.Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs1994; 43:456-460.
69.
69. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease [letter]. Mov Disord2001; 17:221-225.
70.
70. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J NeuropsychiatryClin Neurosci2000; 12:364-369.
71.
71. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology1999; 52:782-785.
72.
72. David SR, Taylor CC, Kinon BJ, Breier A.The effects of olanza-pine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther2000; 22:1085-1109.
73.
73. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology1996; 47:1085-1087.
74.
74. Jimenez-Jimenez FJ, Talon-Barranco A, Orti-Pareja et al. Olanzapine can worsen Parkinsonism. Neurology1998; 50:1183-1184.
75.
75. Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology1998; 50:1195-1196.
76.
76. Aarsland D, Larsen JP, Lim NG, Tandberg E.Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J Neuropsychiatry Clin Neurosci1999; 11:392-394.
77.
77. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology2000; 55:789-794.
78.
78. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology2000; 55:795-799.
80. Reddy S, Factor S, Molho E, Feustel P.The effect of quetiapine on psychosis and motor function in patients with and without dementia. Mov Disord2002; 17:676-681.
81.
81. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term quetiapine use for drug induced psychosis among parkinsonian patients. Mov Disord2003; 18:510-515.
82.
82. Ondo WG, Vuong KD, Ringholz G.Quetiapine for drug-induced psychosis in Parkinson’s disease: a double-blind, placebo-controlled, parallel trial. Mov Disord2003; 18:1083-1083.
83.
83. Morgante L, Epifano A, Spina E, et al. Quetiapine versus cloza-pine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci2002; 23(Suppl 2):S89-S90.
84.
84. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract2002; 8:81-98.
85.
85. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminary experience. Clin Neuropharmacol, in press.
86.
86. Cunningham D, Hawthorn J, Pople A, et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet1987; 1:1461-1463.
87.
87. White A, Corn TH, Feetham C, Faulconbridge C.Ondansetron in treatment of schizophrenia [letter]. Lancet1991; 337:1173-1173.
88.
88. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci1992; 13:116-121.
89.
89. Zoldan J, Friedberg G, Livneh M, Melamed E.Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology1995; 45:1305-1308.
90.
90. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology1996; 47:1608-1609.
91.
91. Shea C, MacKnight C, Rockwood K.Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr1998; 10:229-238.
92.
92. Hutchinson M, Fazzini E.Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry1996; 61:324-325.
93.
93. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol1992; 15:322-325.
94.
94. Albuquerque EX, Santos MD, Alkondon M, et al. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord2001; 15:S19-S25.
95.
95. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry2003; 18:937-941.
96.
96. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord2001; 16:1171-1195.
97.
97. Bullock R, Cameron A.Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin2002; 18:258-264.
98.
98. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet2000; 356:2031-2036.
99.
99. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci2002; 23:41-43.
100.
100. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol2003; 16:184-188.
101.
101. Aarsland D, Laake K, Larsen JP, Janvin C.Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry2002; 72:708-712.
102.
102. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology1994; 44:2308-2314.
103.
103. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry2003; 18:988-993.
104.
104. Onofrj M, Thomas A.Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology2003; 61:1452-1452.
105.
105. Hoflich G, Burghof KW, Kasper S, Moller HJ. Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease [abstract]. Nervenarzt1994; 65:202-205.
106.
106. Hurwitz TA, Calne DB, Waterman K.Treatment of dopaminomimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci1988; 15:32-34.
107.
107. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord2003; 18:831-832.
108.
108. Wykes T, Parr A, Landau S.Group treatment of auditory hallucinations. Exploratory study of effectiveness. Br J Psychiatry1999; 175:180-185.
109.
109. Lee K, Hannan C, van den Bosch JA, et al. Evaluating a hearing voices group for older people: preliminary findings [letter]. Int J Geriatr Psychiatry2002; 17:1079-1080.
